OLEMA PHARMACEUTICALS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $38.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-16
- OLEMA PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $38.89M, a 18.13% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $32.92M, a 36.32% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $24.15M, a 8.37% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $26.36M, a 90.50% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $38.89M 10-K · filed 2026-03-16 |
| 2024-12-31 | $32.92M 10-K · filed 2026-03-16 |
| 2023-12-31 | $24.15M 10-K · filed 2025-03-18 |
| 2022-12-31 | $26.36M 10-K · filed 2024-03-11 |
| 2021-12-31 | $13.84M 10-K · filed 2023-03-09 |
| 2020-12-31 | $4.52M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |